Department of Respiratory Medicine, Pilot Unit for the Management of Rare Intrathoracic Tumors, Louis Pradel Hospital, Lyon 69677, France.
Thorac Surg Clin. 2011 Feb;21(1):115-23, viii. doi: 10.1016/j.thorsurg.2010.08.004.
Significant efforts have been made to dissect the molecular pathways involved in the carcinogenesis of thymic malignancies. Research is hampered by the rarity of the tumor, controversies about histopathologic classification, and the lack of established cell lines and animal models. Insights into the biology of these tumors have been made following anecdotal clinical responses to targeted therapies. This article reviews current knowledge about the molecular data that define molecular subsets and support the use of targeted therapies in thymic tumors.
已经做出了重大努力来剖析胸腺恶性肿瘤发生过程中涉及的分子途径。但是，由于肿瘤罕见、组织病理学分类存在争议以及缺乏已建立的细胞系和动物模型，研究受到了阻碍。通过对靶向治疗的偶然临床反应，对这些肿瘤的生物学有了一些了解。本文回顾了关于定义分子亚群的分子数据的现有知识，并支持在胸腺瘤中使用靶向治疗。
